Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.

Archives of drug information·2009
Same author

Lessons in initiating insulin in clinical practice.

Diabetes research and clinical practice·2008
Same author

A survey study on diabetes management and complication status in primary care setting in Thailand.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet·2007
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glycaemic control and hypoglycaemia in the PRESENT study.

Majeed Almustafa1, Jing Ping Yeo, Duma Khutsoane

  • 1National Diabetes Center, Al Mstansiriya University, Baghdad, Iraq. majeedmustafa@hotmail.com

Diabetes Research and Clinical Practice
|August 9, 2008
PubMed
Summary

Biphasic insulin aspart 30 (BIAsp 30) effectively improves glycemic control in diverse type 2 diabetes patients. This study shows BIAsp 30 is safe and effective across various ages, BMIs, and ethnicities, with low hypoglycemia rates.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jul 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Area of Science:

  • Endocrinology
  • Diabetes Mellitus Research
  • Pharmacotherapy

Background:

  • Type 2 diabetes management requires effective glycemic control.
  • Biphasic insulin aspart 30 (BIAsp 30) is a commonly used insulin therapy.
  • Individual patient characteristics may influence treatment efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of BIAsp 30 in a diverse population with type 2 diabetes.
  • To analyze treatment outcomes across predefined subgroups based on age, BMI, and ethnicity.
  • To assess glycemic control and hypoglycemia rates in different patient demographics.

Main Methods:

  • Multinational observational study (PRESENT) over 6 months.
  • Inclusion of patients with type 2 diabetes on BIAsp 30.
  • Subgroup analysis by age, BMI, and ethnic origin.

Main Results:

  • Similar HbA1c levels achieved across age and BMI subgroups.
  • Black ethnic group had higher baseline HbA1c but achieved significant improvement.
  • Low rates of major hypoglycemia (<1% in any subgroup) observed across all groups.

Conclusions:

  • BIAsp 30 demonstrates effective glycemic control in type 2 diabetes patients across diverse demographics.
  • The insulin therapy is well-tolerated with low hypoglycemia risk in various age, BMI, and ethnic groups.
  • BIAsp 30 is a viable treatment option for achieving clinically relevant glycemic improvements.